My last coverage of Crispr Therapeutics (NASDAQ: CRSP ) and Intellia Therapeutics (NASDAQ: NTLA ) was published in May 2025 . At the time, gene therapy stocks were suffering from regulatory uncertainties, potential pricingOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in life sciences to assess the potential o ...